Degarelix acetate - CAS 214766-78-6
Catalog number:
Not Intended for Therapeutic Use. For research use only.
GNRH Receptor
Publictions citing BOC Sciences Products
  • >> More
FE200486, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prol
1.[Histrelin acetate--the first once yearly LHRH agonist].
Altarac S1. Lijec Vjesn. 2011 Sep-Oct;133(9-10):320-2.
Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.
2.Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
Smith MR1, Klotz L, Persson BE, Olesen TK, Wilde AA. J Urol. 2010 Dec;184(6):2313-9. doi: 10.1016/j.juro.2010.08.012. Epub 2010 Oct 16.
PURPOSE: We assessed the cardiovascular safety profile of degarelix, a new gonadotropin-releasing hormone antagonist.
3.Degarelix acetate for the treatment of prostate cancer.
Klotz L1. Drugs Today (Barc). 2009 Oct;45(10):725-30. doi: 1396674/dot.2009.45.10.1417873.
Pharmacological methods of achieving androgen deprivation for the treatment of prostate cancer have evolved. New strategies are focusing on avoidance of the undesirable effects of testosterone surges or flares associated with the initial stages of gonadotropin-releasing hormone (GnRH) agonists and the significant histamine-mediated side effects that can be associated with GnRH antagonists. Degarelix acetate (Firmagon; Ferring Pharmaceuticals) is a third-generation GnRH antagonist that has been shown to produce a significantly more rapid medical castration (without testosterone surge) and prostate-specific antigen response compared with GnRH agonists. The safety profile is comparable to GnRH agonists and anaphylactic reactions have not been reported. Degarelix is currently available as a 1-month subcutaneous injection and has been approved for the treatment of advanced prostate cancer.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GNRH Receptor Products

CAS 74381-53-6 Leuprolide Acetate

Leuprolide Acetate
(CAS: 74381-53-6)

Triptorelin pamoate
(CAS: 124508-66-3)

Triptorelin is a decapeptide as a GnRH (gonadotropin-releasing hormone) agonist under the development of Pfizer. It decreases pituitary secretion of gonadotropi...

CAS 145781-92-6 Goserelin Acetate

Goserelin Acetate
(CAS: 145781-92-6)

Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pitui...

CAS 86220-42-0 Nafarelin Acetate

Nafarelin Acetate
(CAS: 86220-42-0)

Nafarelin is a GnRH (gonadotropin-releasing hormone) agonist . Its proposed mechanism of action is the desensitization of pituitary gonadotropin-releasing hormo...

CAS 834153-87-6 Elagolix

(CAS: 834153-87-6)

Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ult...

CAS 57773-65-6 Deslorelin

(CAS: 57773-65-6)

Deslorelin is a synthetic nonapeptide analogue of the natural gonadotrophin releasing hormone super-agonist (GnRH agonist) with potential antineoplastic activit...

CAS 33515-09-2 Gonadorelin

(CAS: 33515-09-2)

Gonadorelin, a synthetic decapeptide prepared using solid phase peptide synthesis, is another name for gonadotropin-releasing hormone (GnRH) for evaluating th...

CAS 65807-02-5 Goserelin Acetate

Goserelin Acetate
(CAS: 65807-02-5)

CAS 832720-36-2 Elagolix sodium

Elagolix sodium
(CAS: 832720-36-2)

Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of end...

CAS 214766-78-6 Degarelix acetate

Degarelix acetate
(CAS: 214766-78-6)

CAS 79561-22-1 Alarelin Acetate

Alarelin Acetate
(CAS: 79561-22-1)

Alarelin acetate is a synthetic Gonadotrophin-releasing hormone agonist. It is the acetate form of a hypothalamic peptide. It is a potent LH-RH agonist in rats ...

CAS 76712-82-8 Histrelin

(CAS: 76712-82-8)

Histrelin is a nonapeptide analog of GnRH (gonadotropin-releasing hormone) with added potency. When present in the bloodstream, it can act on gonadotropes. Hist...

CAS 34973-08-5 Gonadorelin acetate

Gonadorelin acetate
(CAS: 34973-08-5)

Gonadorelin a synthetic decapeptide prepared for gonadotropin-releasing hormone (GnRH), affects follicle stimulating hormones.

CAS 53714-56-0 Leuprorelin

(CAS: 53714-56-0)

Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer.

CAS 148029-26-9 Alarelin

(CAS: 148029-26-9)

Alarelin, more commonly existed as Alarelin acetate, has been found to be a GnRH agonist that could delay the sexual maturation in rats.

Chemical Structure

CAS 214766-78-6 Degarelix acetate

Quick Inquiry

Verification code

Featured Items